Smith Nicholas Conrad sold $3.6M of ANRO
Smith Nicholas Conrad (PRESIDENT AND CFO) sold 134,886 shares of Alto Neuroscience, Inc. (ANRO) at an average of $26.45 ($25.78–$26.87, $3.57M total) across 3 trades over 2026-09-29 to 2026-09-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds supply to the market and may slightly depress the stock price, though the pre‑arranged plan suggests it is not a reaction to new information.
Market read
Primary source filing; modest impact due to insider sell size relative to market cap.
What to watch
Potential upcoming financing or dilution events that prompted the insider to reduce exposure.
Background
SEC Form 4 filing discloses an insider sale by the CFO of Alto Neuroscience, Inc.
Ticker impact
Form 4 shows CFO sold 134,886 shares for $3.57M, reducing his stake to 24,060 shares.
likely modest downward pressure as investors price in the insider sell.
The sale is sizable for a micro‑cap and executed via a 10b5‑1 plan, suggesting a planned reduction rather than panic, but still adds supply.
Market effects
Minimal; the sale does not affect the broader neuro‑tech sector.
None; the company is US‑listed and the transaction is company‑specific.
Low; no spillover to other markets.
Counterpoint
The sale could be routine under a 10b5‑1 plan and not reflect negative outlook.
Key entities
- companyAlto Neuroscience, Inc.
Biotech firm focused on neuroscience therapeutics.
- personSmith Nicholas Conrad
President and CFO of Alto Neuroscience, insider seller.